NuvOx Pharma is developing a platform of oxygen therapeutics based on dodecafluoropentane emulsion (DDFPe).
Dodecafluoropentane emulsion (DDFPe) is an injectable drug that travels through the bloodstream arriving first at the lungs to pick up oxygen and finally to hypoxic tissue where it passively delivers the oxygen.
NuvOx’s oxygen therapeutic was tested as a radiosensitizer in a Phase Ib/II clinical trial in brain cancer. The promising results from this study have led the FDA to allow a subsequent Phase II clinical trial in brain cancer to determine if it improves the efficacy of radiation and chemotherapy.
Animal studies show that our oxygen therapeutic can reduce neurological damage from stroke by 85%. A Phase Ib/II clinical trial in humans is ongoing in this indication.
NuvOx’s oxygen therapeutic will be tested in humans to determine if the drug is an effective treatment for acute crisis in sickle cell disease. A Phase Ib clinical trial is planned to start in sickle cell patients in Ghana.
Animal studies using NuvOx’s oxygen therapeutic have shown improved outcomes in heart attack, severe blood loss, and traumatic brain injury.
NuvOx Pharma’s oxygen therapeutics have approved Investigational New Drug applications for a Phase II clinical trial in brain cancer, a Phase Ib/II clinical trial in stroke, and a Phase Ib trial in sickle cell disease.
NuvOx Pharma is a biotechnology company based in Tucson, Arizona developing an innovative platform of oxygen therapeutics to treat life-threatening diseases where hypoxia plays a role. NuvOx's formulations are based on dodecafluoropentane emulsion (DDFPe). Upon intravenous administration, DDFPe travels through the bloodstream arriving first at the lungs to pick up oxygen and finally to hypoxic tissue where it passively delivers the oxygen. Pre-clinical data has shown efficacy in several indications including hypoxic solid tumors, stroke, sickle cell crisis, hemorrhagic shock, traumatic brain injury, and myocardial infarction. Compared to prior fluorocarbons, NuvOx’s DDFPe is active at less than 1/200th the dose (prior agent failed due to high doses and adverse side effects). The company is in the clinical stage for oncology, stroke, and sickle cell crisis.